AEterna Zentaris Inc. (AEZS)

[alexander77]

No way a RS will happen,with $50m in cash and using the Adam Feuersteins' biotech oncology rule and Maxim buy target, it should easily be above $1/share in 6 months

Adam Feuerstein:
Every company with phase 3 oncology treatment which faces a definite FDA decision about yes/no to start commercialization should have a market cap of at least $300million to have a chance for FDA approval. IMO this phase 3 product which would be the first FDA approved product to treat recurrent endometrial cancer has a very good chance for approval. Not calculationg $50m cash, another phase 3 product to diagnose Adult Growth Hormone Deficiency, another phase 2 oncology product, nor the commercialization of Estrogel and soon Saizen as well, AEZS should have a market cap of at least $300 million in 10 months, or when fully diluted in outstanding shares, a PPS of 2.5 dollar/share.

Maxim:
Maxim reiterates $2/share buy target.

Maxim Group’s healthcare analyst Jason Kolbert came out with a research report on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) following the news that the company has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. The analyst reiterated a Buy rating with a $2 price target, which implies an upside of 627% from current levels.

Kolbert observed, “We see compelling value ahead in this company across multiple programs. Success with the pivotal program is not being factored into the current valuation by wall street in our opinion nor is the return of Macrilen. In fact we see Macrilen as representing a paradigm shift in the adult growth hormone deficiency (AGHD) marketplace. The current test, insulin tolerance is long and burdensome compared to Macrilen. As such Macrilen could expand the market.”

The analyst concluded, “We see the current Macrilen trial as low risk, high reward. Other near-term catalysts should support and drive valuation.”

http://www.smarteranalyst.com/2015/07/02/maxim-shines-light-on-aeterna-zentaris-inc-usas-phase-3-zoptec-clinical-study/